Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00475020 · ClinicalTrials.gov registry record · Phase 2
Allogeneic Stem Cell Transplantation for Myelofibrosis and Myelodysplastic Syndrome
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 63
- Enrollment target
NCT00475020: Completed Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT00475020 is a Phase 2 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 63 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00475020, a Phase 2 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 63 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to learn if using a combination of fludarabine, busulfan, and antithymocyte globulin (ATG) can help to control myelofibrosis or myelodysplastic syndrome in patients receiving a bone marrow or blood stem cell transplant. The safety of these drugs will also be studied.
Interventions
- DRUG Fludarabine
- DRUG Busulfan
- DRUG Thymoglobulin (ATG)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2006-01-04 |
| Est. Completion | 2017-10-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00475020
The ClinicalTrials.gov registry entry for NCT00475020 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 63 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Fludarabine is the first listed.
NCT00475020 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00475020 about?
NCT00475020 is a clinical study titled "Allogeneic Stem Cell Transplantation for Myelofibrosis and Myelodysplastic Syndrome". The goal of this clinical research study is to learn if using a combination of fludarabine, busulfan, and antithymocyte globulin (ATG) can help to control myelofibrosis or myelodysplastic syndrome in patients receiving a bone marrow or blood stem cell transplant. The safety of these drugs will also ...
What is the current status of trial NCT00475020?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 63 participants. The study started on 2006-01-04. Estimated completion is 2017-10-04.
What interventions are being tested in trial NCT00475020?
The interventions under investigation include: Fludarabine (DRUG), Busulfan (DRUG), Thymoglobulin (ATG) (DRUG).
Who is sponsoring clinical trial NCT00475020?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.